CRESCENT BIOPHARMA, INC. Revenue from Contract with Customer, Including Assessed Tax
CRESCENT BIOPHARMA, INC. (CBIO) reported Revenue from Contract with Customer, Including Assessed Tax of $10.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2025-02-13
- CRESCENT BIOPHARMA, INC. revenue from contract with customer, including assessed tax for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- CRESCENT BIOPHARMA, INC. revenue from contract with customer, including assessed tax for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- CRESCENT BIOPHARMA, INC. revenue from contract with customer, including assessed tax for the quarter ending 2022-06-30 was $75.00K, a 52716.90% increase year-over-year.
- CRESCENT BIOPHARMA, INC. revenue from contract with customer, including assessed tax for the quarter ending 2021-12-31 was $17.63K, a 89.18% decline year-over-year.
- CRESCENT BIOPHARMA, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $10.00K, a 86.67% decline from fiscal 2022.
- CRESCENT BIOPHARMA, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $75.00K, a 93.53% decline from fiscal 2021.
- CRESCENT BIOPHARMA, INC. revenue from contract with customer, including assessed tax for fiscal 2021 was $1.16M, a 88.59% decline from fiscal 2020.
- CRESCENT BIOPHARMA, INC. revenue from contract with customer, including assessed tax for fiscal 2020 was $10.16M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 1 month | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $10.00K 10-K · filed 2025-02-13 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $0.00 derived: sum of 2 quarters · filed 2024-03-27 | $75.00K derived: sum of 3 quarters · filed 2024-03-27 | $75.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $75.00K derived: sum of 2 quarters · filed 2023-11-03 | $75.00K 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $75.00K 10-Q · filed 2023-08-02 | $75.00K 10-Q · filed 2023-08-02 | |||
| 2021-12-31 | $17.63K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $104.19K derived: sum of 2 quarters · filed 2024-03-27 | $104.33K derived: sum of 3 quarters · filed 2024-03-27 | $1.16M 10-K · filed 2024-03-27 | |
| 2021-09-30 | $86.56K 10-Q · filed 2022-11-09 | $86.70K derived: sum of 2 quarters · filed 2022-11-09 | $1.14M 10-Q · filed 2022-11-09 | $1.31M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-06-30 | $142.00 10-Q · filed 2022-08-03 | $1.06M 10-Q · filed 2022-08-03 | $1.22M derived: sum of 3 quarters · filed 2023-03-29 | $2.22M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2021-03-31 | $1.06M 10-Q · filed 2022-04-28 | $1.22M derived: sum of 2 quarters · filed 2023-03-29 | $2.22M derived: sum of 3 quarters · filed 2023-03-29 | $2.22M derived: sum of 4 quarters · filed 2023-03-29 | |
| 2020-12-31 | $162.94K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.16M derived: sum of 2 quarters · filed 2023-03-29 | $1.16M derived: sum of 3 quarters · filed 2023-03-29 | $10.16M 10-K · filed 2023-03-29 | |
| 2020-09-30 | $1.00M 10-Q · filed 2021-11-02 | $1.00M derived: sum of 2 quarters · filed 2021-11-02 | $10.00M 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $9.00M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $9.00M 10-Q · filed 2021-05-03 | ||||
| 2016-12-31 | $18.50K 10-K · filed 2019-03-06 | ||||
| 2015-06-30 | $20.00M 10-K · filed 2019-03-06 | ||||
| 2014-05-31 | $15.00M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |